Bacterial Infection
62
2
2
51
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
14 trials with published results (23%)
Research Maturity
51 completed trials (82% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
4.8%
3 terminated out of 62 trials
94.4%
+7.9% vs benchmark
26%
16 trials in Phase 3/4
27%
14 of 51 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 51 completed trials
Clinical Trials (62)
Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
Grinding Versus Standard Methods for the Treatment of Per-operative Bacteriological Samples Associated With Osteo-articular Sepsis
EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS
Safety of Intravenous Apramycin in Adults
Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)
Intravenous Fosfomycin Pharmacokinetics Study
Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Minocycline Pharmacokinetics (ACUMIN)
: Bacterial Infections in Injecting Drug Users
Preventing Bacterial and Viral Infections Among Injection Drug Users
Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis
Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm
Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg
Exposure to NSAIDs (Non Steroidal Anti-Inflammatory Drugs) and Severity of Community-acquired Bacterial Infections